Nigeria Targets 70% Local Production of Essential Medicines by 2030 as Pharma Investment Drive Expands

By Simpson Global Media News Desk

Nigeria is targeting at least 70 per cent local production of essential healthcare products by 2030, as the Federal Government steps up efforts to reduce dependence on imported medicines, strengthen pharmaceutical manufacturing and build greater resilience into the country's health supply chain.

The Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, announced the target at the opening of the 8th Nigeria Pharma Manufacturers Expo in Lagos on September 28, where pharmaceutical manufacturers, regulators, investors, technology providers and other industry stakeholders gathered to discuss the future of medicine production in Nigeria and across Africa.

The government says the target is being supported by the Presidential Initiative to Unlock the Healthcare Value Chain (PVAC), a programme designed to increase domestic production of pharmaceuticals, medical devices, diagnostics and other healthcare commodities.

According to Salako, PVAC has secured commitments of about US$2 billion in financing at single-digit interest rates, with roughly 50 Nigerian health firms in advanced funding discussions.

The initiative is also expected to support production of active pharmaceutical ingredients, rapid diagnostic tests and other essential health commodities.

The announcement places pharmaceutical manufacturing at the centre of Nigeria's broader effort to strengthen health security.

It also comes as manufacturers, regulators and policymakers debate whether existing incentives, infrastructure, energy supply, financing arrangements and procurement policies are sufficient to move the industry from a predominantly import-dependent system towards a larger domestic manufacturing base.

From Import Dependence to Medicine Security

The government's argument is that medicine security cannot depend entirely on international supply chains.

Nigeria imports a substantial share of the healthcare products it uses, leaving the country exposed to disruptions in global production, shipping, foreign-exchange movements and changes in international financing.

The COVID-19 pandemic demonstrated how quickly international supply chains can become constrained.

The Federal Ministry of Health and Social Welfare said the pandemic, together with changes in global healthcare financing, reinforced the need for Nigeria and other African countries to develop stronger domestic capacity for producing medicines, vaccines, diagnostics and other critical health technologies.

Salako described medicine security as a question of national resilience.

The policy emphasis is therefore not simply about manufacturing medicines because imported products are expensive.

It is also about ensuring that Nigeria has domestic production capabilities that can continue operating when international supply chains are disrupted.

The government says the ultimate objective is to create a pharmaceutical system that can provide a larger proportion of the medicines Nigerians need from within the country.

That would require investment not only in finished medicines but also in the upstream stages of pharmaceutical production.

Those stages include active pharmaceutical ingredients, excipients, packaging materials, laboratory testing, quality-control systems, machinery, specialised engineering, research and development and the skilled workforce needed to operate modern manufacturing facilities.

The 70 Per Cent Target

The 70 per cent target is ambitious.

The Federal Ministry of Health said Nigeria's local manufacturing capacity has been improving and that the government intends to accelerate that progress through financing, fiscal measures, procurement reforms and other interventions.

In July, the ministry said local manufacturing accounted for nearly half of healthcare products consumed in Nigeria, while the number of registered pharmaceutical companies had risen from 180 in 2022 to more than 200 by 2025.

The ministry also said Nigeria now hosts Africa's second-largest rapid diagnostic test manufacturing plant and is preparing for the establishment of what it described as the first active pharmaceutical ingredients manufacturing plant in sub-Saharan Africa.

These developments are important because finished-dose medicine manufacturing alone does not remove all external dependencies.

A pharmaceutical company can produce tablets or capsules locally while still importing the active ingredient and other critical inputs.

For that reason, the government's emphasis on APIs is strategically important.

An active pharmaceutical ingredient is the substance in a medicine that produces the intended therapeutic effect.

If Nigerian manufacturers continue to import most of their APIs, local production of finished medicines can remain vulnerable to external supply disruptions and foreign-exchange pressures.

The move towards domestic API production is therefore intended to deepen the manufacturing base.

What PVAC Is Designed to Do

The Presidential Initiative to Unlock the Healthcare Value Chain is the central policy mechanism behind the latest push.

The initiative was created to strengthen local production of healthcare products and attract investment into pharmaceutical manufacturing, medical devices and other health-related industries.

The International Finance Corporation has described PVAC as a government initiative intended to transform Nigeria's healthcare ecosystem by increasing local manufacturing and strengthening the role of private investment.

PVAC's strategy reflects a recognition that government funding alone cannot finance the scale of infrastructure required.

Modern pharmaceutical plants require substantial capital.

They also require reliable electricity, water, specialised equipment, laboratory systems, quality-control infrastructure, regulatory compliance and a steady supply of raw materials.

Manufacturers must meet Good Manufacturing Practice requirements and maintain consistent quality before medicines can be supplied to patients.

The initiative therefore attempts to address the pharmaceutical sector as a complete value chain rather than treating medicine manufacturing as an isolated activity.

Financing Is Central to the Plan

One of the most significant announcements from the Lagos expo was the reported financing commitment of about US$2 billion under PVAC.

The Federal Government says the funds are being made available at single-digit interest rates, with approximately 50 Nigerian health firms at advanced stages of financing discussions.

The financing structure matters because pharmaceutical manufacturing is capital-intensive.

Companies need money to construct or upgrade factories, install production equipment, establish laboratories, obtain certifications, expand warehouses and invest in specialised technology.

High borrowing costs can make those investments difficult.

Access to longer-term financing at lower rates can potentially improve the economics of local manufacturing.

However, financing commitments are not the same thing as money already deployed into completed factories.

The effectiveness of the initiative will ultimately depend on how much financing reaches eligible companies, how quickly projects are implemented, what capacity is created and whether those facilities remain commercially viable.

Those are outcomes that will have to be measured over time.

The Power Problem

Electricity is one of the industry's major structural challenges.

Pharmaceutical production requires consistent power for manufacturing equipment, refrigeration, laboratory operations, environmental controls, water systems and storage.

An interruption in electricity can disrupt production and increase costs.

Manufacturers have therefore repeatedly called for measures to reduce energy costs and improve reliability.

Ahead of the September expo, the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria said high energy costs remained a major obstacle to the competitiveness of local pharmaceutical production.

The group urged the Federal Government to create a more investment-friendly environment and improve the conditions required for domestic manufacturing.

The problem goes beyond the pharmaceutical sector.

Nigerian manufacturers across different industries have long identified electricity and other infrastructure costs as major components of their operating expenses.

For pharmaceutical companies, however, the issue has additional implications because medicines must be manufactured and stored under controlled conditions.

The government's local-production target will therefore depend partly on whether manufacturers can obtain reliable energy at costs that allow them to compete with imported products.

Why APIs Matter

Active pharmaceutical ingredients represent one of the most important gaps in the local pharmaceutical value chain.

Nigeria can manufacture finished medicines domestically while importing the ingredients required to make them.

That arrangement provides some local industrial capacity, but it leaves manufacturers exposed to external shocks.

An API manufacturing base would allow Nigerian companies to source a larger share of critical inputs locally.

It could also create opportunities for chemical manufacturing, specialised research, laboratory testing and other industries connected to pharmaceutical production.

The Federal Ministry of Health has said the government is preparing to establish an API manufacturing plant in Nigeria and is using the PVAC initiative to encourage greater local production.

The pharmaceutical manufacturers' association has similarly called for clearer and more stable policies around APIs.

Manufacturers argue that a predictable policy environment is necessary if companies are expected to make long-term investments in production facilities.

A factory built to operate for decades cannot be justified easily if the underlying regulatory or tariff environment changes repeatedly.

Regulatory Capacity Will Be Crucial

Increasing local pharmaceutical production also places greater responsibilities on Nigeria's medicines regulator.

The National Agency for Food and Drug Administration and Control (NAFDAC) is responsible for regulating medicines and other products within its mandate.

Local manufacturers must comply with regulatory requirements before their products can be manufactured and marketed.

NAFDAC's current guidelines state that a pharmaceutical product should not be manufactured in Nigeria unless the facility has been inspected, found compliant with Good Manufacturing Practice and issued the appropriate authority to manufacture.

That requirement is important for medicine security.

Producing more medicines domestically only improves health security if those medicines meet appropriate quality and safety standards.

A rapid expansion in manufacturing capacity without effective regulation could create other risks.

The government's challenge is therefore twofold.

It must make it easier and more commercially viable for legitimate manufacturers to invest while maintaining regulatory standards that protect patients.

NAFDAC's role becomes increasingly important as domestic production expands.

Evidence of a Changing Market

NAFDAC has previously reported signs that Nigeria's pharmaceutical manufacturing landscape is changing.

A September report citing NAFDAC Director-General Prof Moji Adeyeye said that, as of June 2026, 176 pharmaceutical companies had undergone layout reviews involving existing and new companies.

The report also said NAFDAC had recorded a shift in the ratio of imported to locally manufactured pharmaceutical products from approximately 70:30 in 2019 to 50:50 in 2025.

NAFDAC also reported growth in contract manufacturing, with the number of companies engaged in such arrangements rising from 10 in 2019 to 87 in 2026, according to the same report.

Contract manufacturing can allow companies without their own large production facilities to work with established manufacturers that already possess compliant plants and production expertise.

That can reduce barriers to market entry and help increase utilisation of existing manufacturing capacity.

It can also strengthen connections among Nigerian pharmaceutical companies.

But the reported 50:50 ratio should not be interpreted as meaning Nigeria has already achieved full medicine independence.

Local production can still depend heavily on imported raw materials, APIs, equipment and other inputs.

And the government's own 70 per cent target indicates that significant work remains.

Import Substitution Is the Bigger Test

The economic case for local pharmaceutical manufacturing ultimately depends on whether domestic production can replace a meaningful amount of imports while maintaining quality and affordability.

Recent trade data cited by BusinessDay illustrate why that remains an open question.

The publication reported that Nigeria imported pharmaceutical products worth about US$767.4 million in 2023, with imports falling to approximately US$653.5 million in 2024 before rising again to about US$766.2 million in 2025, based on UN Comtrade data compiled by the World Bank.

Those figures do not by themselves measure the success or failure of local manufacturing policies.

Import values can change because of prices, exchange rates, medicine demand, changes in product mix and other factors.

But they do show why import substitution remains an important indicator.

If local production rises while imports also remain high, policymakers will need to determine which products are still being imported and why.

Some medicines may not be commercially viable to manufacture locally.

Others may require technologies or raw materials that are not yet available domestically.

The objective therefore cannot simply be to eliminate imports.

It is to develop competitive domestic capacity where local production makes economic and health-security sense.

The Role of Public Procurement

Government procurement can be another major factor.

Public hospitals and health programmes purchase large quantities of medicines and health commodities.

If public procurement policies give predictable opportunities to compliant domestic manufacturers, companies may have greater confidence to invest in production capacity.

The Federal Ministry of Health has previously highlighted the Medipool Programme, a long-term public-private partnership designed to strengthen local manufacturing through guaranteed public procurement.

The underlying logic is straightforward.

A manufacturer is more likely to invest in a factory if it can reasonably forecast demand.

A government procurement commitment can help provide that predictability.

But procurement policies also have to protect public finances and patients.

Domestic products must meet quality standards and provide value.

The objective should therefore be to create a market in which Nigerian manufacturers can compete on a transparent basis while public buyers retain appropriate quality and value safeguards.

The Cost to Patients

For ordinary Nigerians, the most important question is what greater local production will mean for medicine availability and price.

Nigeria has experienced periods of high medicine costs, influenced by inflation, foreign-exchange movements, import dependence, logistics costs, energy expenses and other factors.

A stronger domestic manufacturing base could reduce some exposure to foreign-exchange shocks.

But local production does not automatically make medicines cheaper.

Manufacturers still face costs for raw materials, machinery, electricity, labour, packaging, quality control, finance and distribution.

If those costs remain high, domestically produced medicines may not automatically undercut imports.

The policy objective therefore has several dimensions.

It is about availability.

It is about resilience.

It is about quality.

It is about affordability.

And it is about building an industrial base that can continue producing during international disruptions.

These objectives can sometimes reinforce one another, but they can also involve trade-offs.

Lessons From the Pandemic

The COVID-19 pandemic remains one of the strongest arguments for strengthening domestic health manufacturing.

During the pandemic, countries around the world competed for personal protective equipment, medicines, vaccines, diagnostic supplies and other health commodities.

International supply chains became strained.

Countries with strong domestic production capacity had greater ability to manufacture some essential products themselves.

For Nigeria, the experience highlighted the risks associated with relying heavily on imported healthcare commodities.

The Federal Ministry of Health explicitly cited the pandemic as one of the factors reinforcing the need for stronger domestic capacity.

The lesson extends beyond pandemics.

Global conflicts, shipping disruptions, commodity shortages and currency crises can all affect medicine supply.

A pharmaceutical supply chain with multiple sources is generally less exposed to a single external disruption than one dependent on a small number of foreign suppliers.

Nigeria's local-production programme is therefore being presented as part of a broader health-security strategy.

The Regional Dimension

The 8th Nigeria Pharma Manufacturers Expo was held under the theme “Regional Manufacturing: Advancing Africa's Pharma and Life-Science Sovereignty through Localization.”

That wording points to a regional ambition.

Nigeria is Africa's most populous country and has one of the continent's largest pharmaceutical markets.

If domestic manufacturers can increase production capacity and meet international quality standards, Nigerian companies could potentially serve markets beyond Nigeria.

The African Continental Free Trade Area creates a framework for greater intra-African trade, although pharmaceutical trade still depends on regulatory harmonisation, manufacturing standards, logistics, tariffs and market-specific requirements.

A larger Nigerian pharmaceutical industry could therefore have implications for West Africa and other African markets.

The objective would not simply be to replace imported medicines with Nigerian products.

It could also involve positioning Nigeria as a manufacturing and distribution centre for parts of the continent.

The Expo's Significance

The two-day Nigeria Pharma Manufacturers Expo brought together manufacturers, regulators, investors, distributors, technology providers and other industry stakeholders in Lagos.

The event was organised by the Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria in collaboration with GPE Expo Pvt. Ltd.

The exhibition included pharmaceutical manufacturing technology, laboratory equipment and discussions around regulatory and investment issues.

The organisers said the event was intended to connect manufacturers and suppliers with technologies and investment opportunities across the West African pharmaceutical market.

Such events are relevant because manufacturing capacity depends on more than pharmaceutical companies themselves.

Factories require specialised machinery.

They need packaging systems.

They need laboratory instruments.

They need water-treatment systems.

They need clean-room technology.

They need quality-control equipment.

They need engineering services.

They need reliable suppliers.

A local pharmaceutical industry therefore supports a wider industrial ecosystem.

Developing the Workforce

Another component of the pharmaceutical manufacturing agenda is human capital.

Modern drug production requires pharmacists, chemists, microbiologists, engineers, laboratory scientists, quality-assurance specialists, regulatory professionals, supply-chain managers and technicians.

The industry's expansion could therefore generate demand for specialised skills.

The Pharmaceutical Manufacturers Group has also placed workforce development on the agenda.

A September 29 panel at the expo was focused on mentoring the next generation of pharmaceutical-industry workers, covering areas including procurement, supply chain, human resources, technical operations and production.

That is significant because manufacturing capacity cannot be sustained by equipment alone.

A new factory needs people who understand production systems, quality assurance, maintenance, regulatory requirements and safety.

Training therefore needs to accompany investment.

Technology and Local Production

Technology transfer is another part of the equation.

Some pharmaceutical manufacturing technologies are highly specialised.

Nigeria can import machinery, but the long-term objective is to build local technical capability around that equipment.

That means developing engineers who can install, maintain and adapt production systems.

It also means strengthening local laboratory capabilities.

If Nigerian companies want to manufacture more complex medicines, they need testing infrastructure capable of demonstrating that products meet required specifications.

The expo's focus on manufacturing technology and laboratory systems reflects that wider requirement.

Technology transfer can also happen through partnerships between Nigerian manufacturers and international companies.

Such arrangements can bring equipment, technical expertise and production know-how into the Nigerian market.

The challenge is to ensure that partnerships create durable domestic capability rather than simply increasing dependence on foreign technology and inputs.

The Importance of Raw Materials

One of the most difficult parts of the 70 per cent target will be localising raw materials.

Manufacturing finished medicines domestically is one step.

Producing the ingredients needed to make them is another.

Nigeria will need to develop capabilities across chemicals, APIs, excipients, packaging and related inputs if it wants to reduce external vulnerabilities throughout the supply chain.

This is why the government's emphasis on API manufacturing is strategically important.

The pharmaceutical industry's domestic supply chain cannot become fully resilient if the most critical ingredients continue to depend on unpredictable international markets.

At the same time, producing every pharmaceutical input domestically may not be economically efficient.

Some ingredients may be cheaper to import because of economies of scale elsewhere.

The policy challenge is therefore to identify strategically important products and inputs where domestic capacity provides clear health or economic benefits.

What Manufacturers Are Asking For

Manufacturers have welcomed the direction of policy but have also identified obstacles.

The Pharmaceutical Manufacturers Group has called for lower energy costs, a more competitive business environment and stable policies supporting API development.

These requests highlight an important point.

A government can announce a local-production target, but private manufacturers ultimately have to invest capital.

They will assess electricity costs, taxes, access to foreign exchange, financing rates, demand, regulation, infrastructure and the predictability of government policy.

If those conditions are unfavourable, companies may postpone investments even when a policy target is ambitious.

Long-term consistency is therefore likely to be important.

Pharmaceutical factories can take years to plan, finance, build and certify.

Investors need confidence that incentives and rules will remain sufficiently stable throughout that period.

Balancing Localisation and Competition

There is also a question about how Nigeria balances support for domestic manufacturers with the need to maintain competition.

Protecting local industry through tariffs or restrictions can provide temporary advantages to domestic producers.

But excessive protection can reduce competitive pressure.

If local manufacturers are shielded from competition without improving productivity, patients could face higher prices or limited product choice.

The government's policy therefore needs to encourage local production while maintaining quality and competitive discipline.

This is particularly important for essential medicines.

Patients cannot simply postpone purchasing an essential drug because a market is temporarily disrupted.

Availability and affordability have direct consequences for health outcomes.

The 2030 Deadline

The government's 2030 target leaves roughly four years for the country to move from the current level of domestic production towards 70 per cent.

That is a relatively short period for large-scale industrial development.

The government will therefore need to track progress through measurable indicators.

These could include the number of new pharmaceutical plants completed, manufacturing capacity added, domestic API production, the share of essential medicines manufactured locally, investment deployed, jobs created, regulatory approvals completed and changes in import dependence.

It will also be important to distinguish between registered manufacturing facilities and actual production.

A company can hold a manufacturing licence without operating at full capacity.

Factory utilisation therefore matters.

So does the ability of manufacturers to maintain production consistently.

Measuring Success Beyond Announcements

The latest announcement provides a policy target and financing commitments.

The next stage is implementation.

That means determining which companies receive financing, what facilities are built, how quickly production begins and which medicines are prioritised.

It also means monitoring whether the additional manufacturing capacity translates into better medicine availability.

For patients, the ultimate measure will not be the number of factories announced.

It will be whether essential medicines are available when needed and whether they are safe, effective and affordable.

For government, success will involve building an industry capable of contributing to national health security.

For manufacturers, success will mean operating commercially sustainable businesses.

For workers, it could mean new opportunities for specialised employment.

For the wider economy, it could mean retaining more value inside Nigeria rather than spending foreign exchange on imported finished products.

The Need for Reliable Data

The 70 per cent target will also require reliable data.

Nigeria needs to know how much of each major category of medicine is consumed.

It needs to know how much is produced domestically.

It needs to know how much is imported.

It needs to know which active ingredients are imported.

It needs to know the production capacity of domestic factories.

And it needs to know whether factories are operating at full or partial capacity.

Without such data, measuring progress can become difficult.

This is another reason the role of regulators and industry associations is important.

Production data, registration data, import data and procurement information need to be sufficiently aligned to provide policymakers with a clear picture of the market.

Medicine Security and Public Health

At its core, the local-manufacturing initiative is a health policy.

A medicine is only useful when it is available to the person who needs it.

A patient with hypertension, diabetes, malaria, tuberculosis or another condition may require uninterrupted access to treatment.

Supply interruptions can lead to delayed treatment, treatment changes or additional costs.

A stronger domestic manufacturing base can potentially reduce some of those risks.

But medicine security also depends on distribution.

Producing medicines in Lagos does not automatically guarantee availability in rural communities.

Warehousing, transportation, cold-chain systems for temperature-sensitive products, state-level procurement and health-facility supply systems remain important.

Local manufacturing is therefore one part of a larger health-supply system.

The Broader Healthcare Value Chain

The Federal Government's strategy extends beyond medicines.

PVAC covers pharmaceuticals, medical devices, diagnostics and other healthcare products.

That broader approach recognises that a modern health system depends on a range of goods.

Hospitals need diagnostic equipment.

Laboratories need testing systems.

Patients need medicines.

Health workers need protective equipment.

Vaccination programmes need cold-chain infrastructure.

Emergency responses require diagnostic and treatment supplies.

Building local capacity across several of these areas could make Nigeria's health system more resilient.

But each industry has its own technical requirements.

A policy that works for basic medicines may not automatically work for sophisticated medical devices.

The government will therefore need sector-specific approaches within the broader healthcare value-chain strategy.

Africa's Pharmaceutical Future

The Lagos expo also reflects a wider African debate about pharmaceutical sovereignty.

African countries collectively remain dependent on imports for many medicines, vaccines and health technologies.

That dependence became particularly visible during the COVID-19 pandemic.

Governments and regional organisations have since placed greater emphasis on local and regional manufacturing.

Nigeria's size gives it a potentially important role in that effort.

If domestic manufacturers can achieve international standards and sufficient scale, Nigerian production could contribute to regional supply.

But this will require cooperation.

Pharmaceutical regulation varies across countries.

Market access rules differ.

Quality standards and registration requirements must be addressed.

Transport and logistics remain major challenges.

The African Continental Free Trade Area provides a framework for greater trade, but practical implementation will require further work.

The Road Ahead

Nigeria's 70 per cent target is now part of an increasingly detailed policy programme.

The Federal Government has identified financing through PVAC.

It has highlighted API production.

It has pointed to local manufacturing growth.

It has introduced initiatives aimed at procurement and health-industry investment.

NAFDAC continues to oversee regulatory standards.

Manufacturers are asking for improved operating conditions.

And industry events such as the Nigeria Pharma Manufacturers Expo are creating spaces where investors, manufacturers and technology providers can interact.

The remaining question is execution.

Over the next four years, the industry will need to turn policy announcements into physical production capacity.

Companies will need to secure financing.

Factories will need to be built or upgraded.

Equipment will need to be installed.

Workers will need to be trained.

Products will need regulatory approval.

Procurement systems will need to create predictable demand.

And patients will ultimately need to see the benefits through improved availability and, where possible, greater affordability.

What Happens Next

The immediate next step is implementation of the financing and investment pipeline announced under PVAC.

The Federal Government says around 50 health firms are in advanced discussions for financing, while about US$2 billion in commitments have been secured at single-digit interest rates.

The government will also need to advance plans for local API production and other essential healthcare commodities.

Manufacturers, meanwhile, are expected to continue pressing for lower energy costs and predictable policies that can support long-term investment.

NAFDAC's regulatory role will become increasingly important as new facilities come online.

The industry will also need to expand its skilled workforce.

And policymakers will need to monitor whether increased manufacturing capacity is translating into genuine reductions in import dependence.

The next four years will therefore provide the practical test of the government's strategy.

A Health Policy With Industrial Consequences

Nigeria's pharmaceutical manufacturing push is unusual because it sits at the intersection of health policy and industrial policy.

It is about medicines, but it is also about factories.

It is about patients, but it is also about investment.

It is about health security, but it is also about jobs and technology.

It is about reducing import dependence, but it is also about building a competitive manufacturing industry.

That combination explains the breadth of the current programme.

The Federal Government wants domestic manufacturers to produce more.

Manufacturers want an environment in which investment is commercially viable.

Regulators want production to meet safety and quality requirements.

Patients need medicines that are available and affordable.

And investors need predictable policies and reliable infrastructure.

All of those interests must be reconciled if the 70 per cent target is to become more than a policy declaration.

The Patient Remains the Final Measure

The ultimate purpose of pharmaceutical localisation is not simply to increase the number of Nigerian-made products.

It is to strengthen the health system.

A domestic medicine industry is valuable if it can reliably supply quality products.

A new factory is valuable if it produces medicines that patients need.

A financing programme is valuable if it creates sustainable manufacturing capacity.

A regulatory system is valuable if it protects patients while allowing legitimate businesses to operate efficiently.

And a local-production target is meaningful if progress can be measured transparently.

Nigeria now has a clearly stated objective: at least 70 per cent local production of essential healthcare products by 2030.

The government says about US$2 billion in financing commitments are supporting the effort, with approximately 50 firms in advanced discussions.

The Ministry of Health has also pointed to growth in pharmaceutical manufacturing, the development of rapid diagnostic production and plans for domestic API capacity.

The pharmaceutical industry, meanwhile, continues to call for improvements in energy costs, investment conditions and policy stability.

These developments establish the direction of travel.

The more difficult task is the one that now begins: converting financing into factories, factories into production, production into reliable supply and reliable supply into better health outcomes.

Nigeria's pharmaceutical industry has four years to demonstrate how far that transition can go.

By 2030, the central question will not simply be whether the country announced a 70 per cent target.

It will be how much of that target was actually achieved — and whether Nigerians experienced a health system that was more resilient, more secure and better able to provide essential medicines when they needed them.